Diagnostic and therapeutic implications of tumor-infiltrating lymphocytes in breast cancer

Journal of Clinical Oncology

Volumn 31, Issue 7, 2013, Pages 836-837

  Denkert, Carsten ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BRCA1 PROTEIN; CALRETICULIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; IMMUNOGLOBULIN KAPPA CHAIN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CELL STRUCTURE; CLINICAL TRIAL (TOPIC); EDITORIAL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE EXPRESSION; GENE MUTATION; HISTOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; LYMPHOCYTE; LYMPHOCYTIC INFILTRATION; MEDULLARY CARCINOMA; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODES; LYMPHOCYTES, TUMOR-INFILTRATING;

EID: 84875696939     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.1698     Document Type: Editorial

References (23)

1. Poste G: Bring on the biomarkers. Nature 469:156-157, 2011.
2. Loi S, Sirtaine N, Piette F, et al: Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 31:860-867, 2013.
3. Denkert C, Loibl S, Noske A, et al: Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28:105-113, 2010.
4. von Minckwitz G, Untch M, Blohmer JU, et al: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30:1796-1804, 2012.
5. Zitvogel L, Apetoh L, Ghiringhelli F, et al: Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8:59-73, 2008.
6. Zitvogel L, Kepp O, Kroemer G: Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 8:151-160, 2011.
7. Senovilla L, Vitale I, Martins I, et al: An immune surveillance mechanism controls cancer cell ploidy. Science 337:1678-1684, 2012.
8. Demaria S: Defining the role of the immune system in cancer treatment: Highlights from the Immune chemotherapy Conference. Expert Rev Anticancer Ther 11:841-843, 2011.
9. Emens LA: Re-purposing cancer therapeutics for breast cancer immunotherapy. Cancer Immunol Immunother 61:1299-1305, 2012.
10. West NR, Milne K, Truong PT, et al: Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res 13:R126, 2011.
11. Schmidt M, Hellwig B, Hammad S, et al: A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors. Clin Cancer Res 18:2695- 2703, 2012.
12. Chen Z, Gerhold-Ay A, Gebhard S, et al: Immunoglobulin kappa C predicts overall survival in node-negative breast cancer. PLoS One 7:e44741, 2012.
13. Rody A, Karn T, Liedtke C, et al: A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res 13:R97, 2011.
14. Moore OS Jr, Foote FW Jr: The relatively favorable prognosis of medullary carcinoma of the breast. Cancer 2:635-642, 1949.
15. Ridolfi RL, Rosen PP, Port A, et al: Medullary carcinoma of the breast: A clinic pathologic study with 10 year follow-up. Cancer 40:1365-1385, 1977.
16. Pedersen L, Zedeler K, Holck S, et al: Medullary carcinoma of the breast, proposal for a new simplified histopathological definition: Based on prognostic observations and observations on inter- and intraobserver variability of 11 histopathological characteristics in 131 breast carcinomas with medullary features. Br J Cancer 63:591-595, 1991.
17. Huober J, Gelber S, Goldhirsch A, et al: Prognosis of medullary breast cancer: Analysis of 13 International Breast Cancer Study Group (IBCSG) trials. Ann Oncol 23:2843-2851, 2012.
18. Lakhani SR, Jacquemier J, Sloane JP, et al: Multi factorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90:1138-1145, 1998.
19. Da Silva L, Lakhani SR: Pathology of hereditary breast cancer. Mod Pathol 23:S46-S51, 2010 (suppl 2).
20. Eisinger F, Jacquemier J, Charpin C, et al: Mutations at BRCA1: the medullary breast carcinoma revisited. Cancer Res 58:1588-1592, 1998.
21. German Breast Group: Addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (Gepar Sixto). http://clinicaltrials.gov/ct2/show/NCT01426880.
22. German Breast Group: Study comparing nanoparticle-based paclitaxel with solvent-based paclitaxel as part of neoadjuvant chemotherapy for patients with early breast cancer (GeparSepto). http://clinicaltrials.gov/ct2/show/ NCT01583426.
23. Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101:1446-1452, 2009.